Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trientine Hydrochloride for Macular Edema Prevention After Cataract Surgery in Type 2 Diabetes
NCT01295073Phase 2Withdrawn
- Sponsor
- University of British Columbia
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in macular edema comparing Trientine Hydrochloride with Placebo (2 arms). Primary endpoint: Change in retinal thickness measurements by Optical Coherence Tomography (OCT) at Day 28. Status: withdrawn.
02
Drugs
trientine hydrochloride
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT01295073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01295073.